Letter

Rapamycin fed late in life extends lifespan in genetically heterogeneous mice

  • Nature volume 460, pages 392395 (16 July 2009)
  • doi:10.1038/nature08221
  • Download Citation
Received:
Accepted:
Published:

Abstract

Inhibition of the TOR signalling pathway by genetic or pharmacological intervention extends lifespan in invertebrates, including yeast, nematodes and fruitflies1,2,3,4,5; however, whether inhibition of mTOR signalling can extend lifespan in a mammalian species was unknown. Here we report that rapamycin, an inhibitor of the mTOR pathway, extends median and maximal lifespan of both male and female mice when fed beginning at 600 days of age. On the basis of age at 90% mortality, rapamycin led to an increase of 14% for females and 9% for males. The effect was seen at three independent test sites in genetically heterogeneous mice, chosen to avoid genotype-specific effects on disease susceptibility. Disease patterns of rapamycin-treated mice did not differ from those of control mice. In a separate study, rapamycin fed to mice beginning at 270 days of age also increased survival in both males and females, based on an interim analysis conducted near the median survival point. Rapamycin may extend lifespan by postponing death from cancer, by retarding mechanisms of ageing, or both. To our knowledge, these are the first results to demonstrate a role for mTOR signalling in the regulation of mammalian lifespan, as well as pharmacological extension of lifespan in both genders. These findings have implications for further development of interventions targeting mTOR for the treatment and prevention of age-related diseases.

  • Subscribe to Nature for full access:

    $199

    Subscribe

Additional access options:

Already a subscriber?  Log in  now or  Register  for online access.

Change history

  • Corrected online 16 July 2009

    A present address author affiliation was added to C.S.C. on 16 July 2009.

References

  1. 1.

    et al. Regulation of yeast replicative life span by TOR and Sch9 in response to nutrients. Science 310, 1193–1196 (2005)

  2. 2.

    , , , & Extension of chronological life span in yeast by decreased TOR pathway signaling. Genes Dev. 20, 174–184 (2006)

  3. 3.

    , & The TOR pathway interacts with the insulin signaling pathway to regulate C. elegans larval development, metabolism and life span. Development 131, 3897–3906 (2004)

  4. 4.

    et al. Regulation of lifespan in Drosophila by modulation of genes in the TOR signaling pathway. Curr. Biol. 14, 885–890 (2004)

  5. 5.

    et al. Genetics: influence of TOR kinase on lifespan in C. elegans. Nature 426, 620 (2003)

  6. 6.

    Principles of Mammalian Aging 2nd edn 151 (Prentice-Hall, 1978)

  7. 7.

    Extending life: scientific prospects and political obstacles. Milbank Q. 80, 155–174 (2002)

  8. 8.

    , , & In pursuit of the longevity dividend. Scientist 20, 28–35 (2006)

  9. 9.

    & in Brockelhurst's Textbook of Geriatric Medicine (eds Tallis, R., Fillit, H. & Brockelhurst, J. C.) 193–199 (Churchill Livingstone, 1998)

  10. 10.

    & l-deprenyl treatment in aged mice slightly increases lifespans, and greatly reduces fecundity by aged males. J Gerontol. Biol. Sci. 51A, B448–B453 (1996)

  11. 11.

    & Life extension. N. Engl. J. Med. 312, 1159–1168 (1985)

  12. 12.

    & Selecting animal models of human aging. Inbred strains often exhibit less biological uniformity than F1 hybrids. J. Gerontol. 49, B1–B11 (1994)

  13. 13.

    et al. Maximum life spans in mice are extended by wild strain alleles. Exp. Biol. Med. 226, 854–859 (2001)

  14. 14.

    , & in The Mouse in Biomedical Research 2nd edn, Vol. III (eds Fox, J. G. et al.) 637–672 (Academic, 2007)

  15. 15.

    et al. An aging interventions testing program: study design and interim report. Aging Cell 6, 565–575 (2007)

  16. 16.

    et al. Design of aging intervention studies: the NIA interventions testing program. AGE 30, 187–199 (2008)

  17. 17.

    et al. Nordihydroguaiaretic acid and aspirin increase lifespan of genetically heterogeneous male mice. Aging Cell 7, 641–650 (2008)

  18. 18.

    Selection for radiation resistance in mice. Genetics 48, 205–216 (1963)

  19. 19.

    , , , & Statistical methods for testing effects on “maximum lifespan”. Mech. Ageing Dev. 125, 629–632 (2004)

  20. 20.

    , , , & mTOR signaling: implications for cancer and anticancer therapy. Br. J. Cancer 96 (Suppl.). R11–R15 (2007)

  21. 21.

    Overview of caloric restriction and ageing. Mech. Ageing Dev. 126, 913–922 (2005)

  22. 22.

    & Evidence for down-regulation of phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR)-dependent translation regulatory signaling pathways in Ames dwarf mice. J. Gerontol. A 60, 293–300 (2005)

  23. 23.

    & Akt/PKB and p38 MAPK signaling, translational initiation and longevity in Snell dwarf mouse livers. Mech. Ageing Dev. 125, 785–798 (2004)

  24. 24.

    et al. Temporal linkage between the phenotypic and genomic responses to caloric restriction. Proc. Natl Acad. Sci. USA 101, 5524–5529 (2004)

  25. 25.

    Rapamycin’s resurrection: a new way to target the cancer cell cycle. J. Natl Cancer Inst. 93, 1517–1519 (2001)

  26. 26.

    & TOR: the first 10 years. Curr. Top. Microbiol. Immunol. 279, 1–18 (2004)

  27. 27.

    , & TOR signaling in growth and metabolism. Cell 124, 471–484 (2006)

  28. 28.

    & Stress and mTORture signaling. Oncogene 25, 6373–6383 (2006)

  29. 29.

    & New modes of translational control in development, behavior, and disease. Mol. Cell 28, 721–729 (2007)

  30. 30.

    A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72, 248–254 (1976)

Download references

Acknowledgements

This work was supported by NIA grants AG022303 (R.A.M.), AG025707 and AG022308 (D.E.H.), AG022307 (R.S.) and AG13319 (J.F.N. and R.S.), and the Department of Veterans Affairs (R.A.M. and R.S.) and DoD W81XWH-07-1-0605 (Z.D.S.). We wish to thank P. J. Krason, P. J. Harrison, E. Adler, V. Diaz, J. Sewald, L. Burmeister, B. Kohler, M. Han, M. Lauderdale and D. Jones for reliable technical assistance, S. Pletcher and A. Galecki for statistical assistance, and H. Warner and S. N. Austad for scientific counsel.

Author Contributions D.E.H., R.S. and R.A.M. serve as the principal investigators at the three collaborating institutions; they were responsible for project design, supervision of technical personnel, interpretation of results, and preparation of manuscript drafts. Z.D.S. proposed rapamycin for the study, and was responsible for the measures of mTOR function. J.F.N. and K. Flurkey provided advice on experimental design and interpretation, and comments on the manuscript. Lab manager C.M.A. provided advice, and supervised laboratory procedures and data collection at The Jackson Laboratory site. N.L.N. served as the project officer for the National Institute on Aging, and contributed to program development, experimental design and analysis. J.E.W. conducted and helped interpret the necropsy analyses. K. Frenkel recommended CAPE for the study, and advised on dose and route of administration. C.S.C. and M.P. recommended enalapril for the study, and advised on dose and route of administration. M.A.J. was responsible for the pharmacological analyses. E.F. supervised and conducted laboratory procedures and data collection at the University of Texas site.

Author information

Author notes

    • David E. Harrison
    • , Randy Strong
    •  & Richard A. Miller

    These authors contributed equally to this work.

    • Christy S. Carter
    •  & Marco Pahor

    Present address: Department of Aging and Geriatric Research, College of Medicine, Institute on Aging, University of Florida, Gainesville, Florida 32611, USA.

Affiliations

  1. The Jackson Laboratory, Bar Harbor, Maine 04609, USA

    • David E. Harrison
    • , Clinton M. Astle
    •  & Kevin Flurkey
  2. Geriatric Research, Education and Clinical Center and Research Service, South Texas Veterans Health Care System, Department of Pharmacology, and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78229, USA

    • Randy Strong
    •  & Elizabeth Fernandez
  3. Institute of Biotechnology/Department of Molecular Medicine, and Barshop Institute for Longevity and Aging Studies, The University of Texas Health Science Center at San Antonio, Texas 78245, USA

    • Zelton Dave Sharp
  4. Department of Physiology and Barshop Institute for Longevity and Aging Studies at The University of Texas Health Science Center at San Antonio, Texas 78229, USA

    • James F. Nelson
  5. Division of Aging Biology, National Institute on Aging, Bethesda, Maryland 20892, USA

    • Nancy L. Nadon
  6. Unit for Laboratory Animal Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan 48109-2200, USA

    • J. Erby Wilkinson
  7. Environmental Medicine, NY University School of Medicine, New York 10016, USA

    • Krystyna Frenkel
  8. Wake Forest University School of Medicine, Department of Internal Medicine: Section on Gerontology and Geriatrics Winston-Salem, North Carolina 27157, USA

    • Christy S. Carter
    •  & Marco Pahor
  9. Department of Psychiatry, The University of Texas Health Science Center at San Antonio, Texas 78229, USA

    • Martin A. Javors
  10. Department of Pathology and Geriatrics Center, University of Michigan, and Ann Arbor VA Medical Center, Ann Arbor, Michigan 48109-2200, USA

    • Richard A. Miller

Authors

  1. Search for David E. Harrison in:

  2. Search for Randy Strong in:

  3. Search for Zelton Dave Sharp in:

  4. Search for James F. Nelson in:

  5. Search for Clinton M. Astle in:

  6. Search for Kevin Flurkey in:

  7. Search for Nancy L. Nadon in:

  8. Search for J. Erby Wilkinson in:

  9. Search for Krystyna Frenkel in:

  10. Search for Christy S. Carter in:

  11. Search for Marco Pahor in:

  12. Search for Martin A. Javors in:

  13. Search for Elizabeth Fernandez in:

  14. Search for Richard A. Miller in:

Corresponding author

Correspondence to David E. Harrison.

Supplementary information

PDF files

  1. 1.

    Supplementary Information

    This file contains Supplementary Methods, Supplementary Tables S1-S2 and Supplementary Figure 1.

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.